In 1957, an Anti-Inflammatory Turned Up in Egg Yolk. Your Body Had Been Making It All Along.

The Oasis Health Journal · Submitted July 24, 2026 · 2:22 PM ET

Around 1954, a few researchers noticed that egg yolk calmed inflammation. This is a strange thing to notice. Egg yolk is not where you go looking for a drug. It is where you go looking for breakfast.

The effect was real, though, and in 1957 a team led by Kuehl pinned down the molecule doing the work. They pulled it out in crystal form from soybean lecithin, from egg yolk, and from defatted peanut meal, and named it N-(2-hydroxyethyl)-palmitamide. Everyone else now calls it palmitoylethanolamide, or PEA, because saying the full name twice is its own kind of injury.

Here is the part that took another few decades to sink in. PEA was not really hiding in the egg. Your own body makes it. Cells produce PEA on demand, right where tissue is irritated, as a sort of local settle-down signal. The egg yolk just happened to carry some too. We spent years extracting a compound from soy and peanuts that human cells had been quietly manufacturing the whole time.

In 1993 the Nobel laureate Rita Levi-Montalcini and her group worked out roughly how it behaves. PEA turns down mast cells, the immune cells that fire off inflammation and pain signals when they get overexcited. She called the idea ALIA, autacoid local injury antagonism, which is a lot of syllables for the body sending in its own bouncer. Later work found PEA does much of this by switching on a receptor called PPAR-alpha. In mice bred without that receptor, PEA stops working, which is a tidy way of proving the receptor is the door it walks through.

The first people to sell PEA were not a supplement company. In 1970 a Czechoslovak drug maker called Spofa released a tablet named Impulsin and handed it to soldiers and schoolchildren to fend off the flu. About six trials ran in nearly 4,000 people. The flu results are old, the methods would not survive a modern review, and nobody takes PEA for the flu today. But the byproduct of dosing 4,000 people is a long safety record, and PEA came out of it looking remarkably boring, in the good way.

The reason PEA is back on the shelf is nerve pain. A 2023 review pooled the double-blind, placebo-controlled trials and found PEA beat placebo by about 1.68 points on an 11-point pain scale. That is a real, noticeable dent, roughly the gap between a bad day and a manageable one. The honest asterisk is large. The trials disagreed with each other a lot (the statisticians put the disagreement at 93 percent, which is high), and many were small. In a 2022 trial, people with diabetic nerve pain took 600 mg a day for eight weeks and reported less pain and less of the burning, prickling interference that makes a sock feel like sandpaper. Other trials tested a micronized form for nerve pain after spinal cord injury.

So PEA is not a painkiller in the aspirin sense. It does not blockade a signal so much as talk an overreacting system back toward baseline, which is slower and gentler and, for chronic nerve pain, sometimes the entire point. It is usually taken as a micronized or ultramicronized powder so the molecule actually gets absorbed instead of just passing through. You can find PEA as capsules and chewables, as micronized palmitoylethanolamide for better uptake, and in formulas that pair it with NAC for people stacking it into a bigger routine.

One detail matters more with a fatty molecule like this than with most. Freshness. PEA is a lipid, and lipids are happiest before they have spent two years aging in a warehouse. We make ours to order instead of pulling from old stock, which is why shipping takes a little longer here than from a fulfillment center the size of an airport. The tradeoff is potency that has not been sitting around losing the plot. If you want it yesterday, we are the wrong store. If you want it fresh, the wait is the feature.

This article is for education only. It is not medical advice, and PEA is sold as a dietary supplement, not an approved drug for any condition. Talk with your own clinician before starting anything new, especially if you take other medicines or manage an ongoing health condition.

Sources

1. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials (Nutrients, 2023)
2. A randomized controlled trial of palmitoylethanolamide for diabetic peripheral neuropathic pain (2022)
3. Effects of PEA on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence (Nutrients, 2022)
4. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial (2016)
5. Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: a PPAR-alpha-Mediated Mechanism (2013)
6. Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold (Int. J. Inflammation, 2013)